FCM
Farallon Capital Management’s Pacific Biosciences PACB Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $167K | Hold |
135,000
| – | – | ﹤0.01% | 119 |
|
|
2025
Q1 | $159K | Hold |
135,000
| – | – | ﹤0.01% | 120 |
|
|
2024
Q4 | $247K | Hold |
135,000
| – | – | ﹤0.01% | 111 |
|
|
2024
Q3 | $230K | Hold |
135,000
| – | – | ﹤0.01% | 130 |
|
|
2024
Q2 | $185K | Sell |
135,000
-3,637,452
| -96% | -$4.98M | ﹤0.01% | 136 |
|
|
2024
Q1 | $14.1M | Sell |
3,772,452
-2,418,918
| -39% | -$9.07M | 0.06% | 84 |
|
|
2023
Q4 | $60.7M | Sell |
6,191,370
-4,032,750
| -39% | -$39.6M | 0.28% | 55 |
|
|
2023
Q3 | $85.4M | Buy |
10,224,120
+1,886,000
| +23% | +$15.7M | 0.4% | 44 |
|
|
2023
Q2 | $111M | Buy |
8,338,120
+1,983,000
| +31% | +$26.4M | 0.56% | 45 |
|
|
2023
Q1 | $73.6M | Buy |
6,355,120
+2,350,720
| +59% | +$27.2M | 0.4% | 51 |
|
|
2022
Q4 | $32.8M | Buy |
+4,004,400
| New | +$32.8M | 0.19% | 70 |
|
|
2022
Q2 | – | Sell |
-1,631,800
| Closed | -$14.8M | – | 322 |
|
|
2022
Q1 | $14.8M | Sell |
1,631,800
-413,688
| -20% | -$3.76M | 0.07% | 114 |
|
|
2021
Q4 | $41.9M | Buy |
2,045,488
+53,238
| +3% | +$1.09M | 0.21% | 70 |
|
|
2021
Q3 | $50.9M | Buy |
1,992,250
+1,742,250
| +697% | +$44.5M | 0.24% | 72 |
|
|
2021
Q2 | $8.74M | Buy |
+250,000
| New | +$8.74M | 0.04% | 138 |
|
|
2021
Q1 | – | Sell |
-2,100,000
| Closed | -$54.5M | – | 244 |
|
|
2020
Q4 | $54.5M | Sell |
2,100,000
-1,963,770
| -48% | -$50.9M | 0.33% | 60 |
|
|
2020
Q3 | $40.1M | Buy |
4,063,770
+1,063,770
| +35% | +$10.5M | 0.28% | 69 |
|
|
2020
Q2 | $10.4M | Hold |
3,000,000
| – | – | 0.08% | 100 |
|
|
2020
Q1 | $9.18M | Hold |
3,000,000
| – | – | 0.08% | 82 |
|
|
2019
Q4 | $15.4M | Buy |
+3,000,000
| New | +$15.4M | 0.1% | 87 |
|